Please provide your email address to receive an email when new articles are posted on . Diarrhea in cancer patients is common and can result from different treatments and toxicities. These include ...

PARSIPPANY, N.J., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of the first and ...

Teva is introducing the only generic version of Novartis AG's Sandostatin LAR Depot, in the United States. Octreotide acetate for injectable suspension is indicated to treat acromegaly and severe ...

Everolimus plus octreotide LAR extended time without tumor growth from 11.3 to 16.4 months versus octreotide LAR alone in advanced NET (carcinoid) patients[1] The study did not reach its primary ...

Viatris Inc. VTRS recently announced four regulatory achievements across multiple stages of its pipeline. These achievements outline the company’s R&D progress in 2025. VTRS will continuously work ...

CAM2029 is an investigational ready-to-use, long-acting octreotide subcutaneous injection depot. Polycystic liver disease is a rare genetic disorder characterized by the progressive growth of more ...

Details concerning the Octreotide medication encompass its pricing as well as its availability in various forms, including tablets, capsules, syrups, creams, gels, ointments, liquids, and injections.

Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia Randomized, single-blinded study. Patients with NETs received ...